Hypercoagulability during induction therapy of acute lymphoblastic leukemia is of scarce clinical relevance. Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto

Blood. 1993 May 1;81(9):2468-9.
No abstract available

Publication types

  • Clinical Trial
  • Comment
  • Comparative Study
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Antithrombin III / analysis
  • Asparaginase / administration & dosage
  • Blood Coagulation* / drug effects
  • Cyclophosphamide / administration & dosage
  • Daunorubicin / administration & dosage
  • Fibrinogen / metabolism
  • Fibrinolysin / analysis
  • Fibrinopeptide A / analysis
  • Humans
  • Peptide Hydrolases / analysis
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Prednisone / administration & dosage
  • Prospective Studies
  • Prothrombin / analysis
  • Vincristine / administration & dosage
  • alpha-2-Antiplasmin / analysis

Substances

  • alpha-2-Antiplasmin
  • antithrombin III-protease complex
  • Fibrinopeptide A
  • Vincristine
  • Cyclophosphamide
  • Antithrombin III
  • Prothrombin
  • Fibrinogen
  • Peptide Hydrolases
  • Fibrinolysin
  • Asparaginase
  • Prednisone
  • Daunorubicin